Medtronic Stent Graft Chosen by U.S. FDA for Innovative Program

MEDTRONIC, INC.

The U.S. Food and Drug Administration (FDA) recently selected a stent graft being developed by Medtronic, Inc. for an early feasibility pilot program that allows for “early clinical evaluation to provide proof of principle and initial clinical safety data.”  One of nine devices selected for the program, the Valiant® Mona LSA system is a stent graft designed to repair a descending thoracic aortic aneurysm encroaching on the left subclavian artery (LSA). The device is based on the market-leading Valiant® Captivia® Thoracic Stent Graft, which is approved by the FDA for treating aneurysms/penetrating ulcers and related conditions of the descending thoracic aorta without major surgery. Learn more at http://bit.ly/LRx3i4.